Opioid system influences gut-brain axis: Dysbiosis and related alterations

Rueda‐Ruzafa, Lola; Cruz, Francisco; Cardona, Diana M.; Hone, Arik J.; Molina-Torres, Guadalupe; Sánchez‐Labraca, Nuria; Román, Pablo

doi:10.1016/j.phrs.2020.104928

Cited by 40 publications

(28 citation statements)

References 141 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…MOPr has a critical role in emotion processing, social behaviour and pain; there is evidence that gut microbiota can affect central MOPr‐mediated behaviours via the gut‐brain axis (GBA) (Ren & Lotfipour, 2020; Rueda‐Ruzafa et al, 2020). Therefore, we investigated in GF rats, the impact of microbiota on the expression of MOPr in forebrain regions at different developmental periods, including early life, where significant neuroadaptations are known to occur.…”

Section: Discussionmentioning

confidence: 99%

Sex‐dependent impact of microbiota status on cerebral μ‐opioid receptor density in fischer rats

Effah

Silva

Katie

et al. 2022

Eur J of Neuroscience

View full text Add to dashboard Cite

μ‐opioid receptors (MOPr) play a critical role in social play, reward and pain, in a sex‐ and age‐dependent manner. There is evidence to suggest that sex and age differences in brain MOPr density may be responsible for this variability; however, little is known about the factors driving these differences in cerebral MOPr density. Emerging evidence highlights gut microbiota's critical influence and its bidirectional interaction with the brain on neurodevelopment. Therefore, we aimed to determine the impact of gut microbiota on MOPr density in male and female brains at different developmental stages. Quantitative [3H]DAMGO autoradiographic binding was carried out in the forebrain of male and female conventional (CON) and germ‐free (GF) rats at postnatal days (PND) 8, 22 and 116–150. Significant ‘microbiota status X sex’, ‘age X brain region’ interactions and microbiota status‐ and age‐dependent effects on MOPr binding were uncovered. Microbiota status influenced MOPr levels in males but not females, with higher MOPr levels observed in GF versus CON rats overall regions and age groups. In contrast, no overall sex differences were observed in GF or CON rats. Interestingly, within‐age planned comparison analysis conducted in frontal cortical and brain regions associated with reward revealed that this microbiota effect was restricted only to PND22 rats. Thus, this pilot study uncovers the critical sex‐dependent role of gut microbiota in regulating cerebral MOPr density, which is restricted to the sensitive developmental period of weaning. This may have implications in understanding the importance of microbiota during early development on opioid signalling and associated behaviours.

show abstract

Section: Discussionmentioning

confidence: 99%

Sex‐dependent impact of microbiota status on cerebral μ‐opioid receptor density in fischer rats

Effah

Silva

Katie

et al. 2022

Eur J of Neuroscience

View full text Add to dashboard Cite

show abstract

“…Opioids receptors are located both in the digestive tract and central nervous system, and its effects on dysbiosis have been largely reported by literature. Moreover, some bacterial components can modify the expression of opioids receptors, changing the tolerance to pain (120). Larger studies are needed to confirm the effect of these medications on gut microbiota composition and outcome.…”

Section: Sedatives Analgesics and Myorelaxantsmentioning

confidence: 99%

The Role of Dysbiosis in Critically Ill Patients With COVID-19 and Acute Respiratory Distress Syndrome

et al. 2021

View full text Add to dashboard Cite

In late December 2019, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) quickly spread worldwide, and the syndrome it causes, coronavirus disease 2019 (COVID-19), has reached pandemic proportions. Around 30% of patients with COVID-19 experience severe respiratory distress and are admitted to the intensive care unit for comprehensive critical care. Patients with COVID-19 often present an enhanced immune response with a hyperinflammatory state characterized by a “cytokine storm,” which may reflect changes in the microbiota composition. Moreover, the evolution to acute respiratory distress syndrome (ARDS) may increase the severity of COVID-19 and related dysbiosis. During critical illness, the multitude of therapies administered, including antibiotics, sedatives, analgesics, body position, invasive mechanical ventilation, and nutritional support, may enhance the inflammatory response and alter the balance of patients' microbiota. This status of dysbiosis may lead to hyper vulnerability in patients and an inappropriate response to critical circumstances. In this context, the aim of our narrative review is to provide an overview of possible interaction between patients' microbiota dysbiosis and clinical status of severe COVID-19 with ARDS, taking into consideration the characteristic hyperinflammatory state of this condition, respiratory distress, and provide an overview on possible nutritional strategies for critically ill patients with COVID-19-ARDS.

show abstract

“…The topic of the capacity of the gut microbiome to regulate pain has been the subject of many recent reviews. Table 1 [8,9,11,[32][33][34][35][36][37][38][39][40][41][42][43][44][45][46][47][48][49][50][51] illustrates and summarizes 23 of these review articles that detail a variety of aspects surrounding pain initiation, detection, biochemistry, and management. As captured among these reviews, there has been an explosion of research on this topic over the past five years.…”

Section: Painmentioning

confidence: 99%

Microbiome First Approaches in Pain Prevention and Management

Dietert

2021

AJBSR

View full text Add to dashboard Cite

The Microbiome First Initiative aims to facilitate sustainable healthcare by focusing first and foremost on the human holobiont majority, the microbiome. Understanding how the human microbiome affects not only risk of disease but also human perceptions can help individuals thrive and pave the way for a healthy life course. Following a recent review of Microbiome First Medicine the context of health and safety, this present opinion article considers the role of the human microbiome, particularly the gut microbiome, on pain, sensory perceptions, and the prevention and multimodal management of pain. Microbial dysbiosis can be causative of some forms of immune-inflammatory and neurologic pain and the altered human microbiome can lock in the pain while at the same time interfering with analgesic/opioid therapies. Dysbiotic microbiota can make drug treatments less effective and with opioids, the microbes can significantly increase:1. Opioid tolerance 2. The risk of addiction 3. The likelihood of withdrawal failure.For these reasons, it is critical to move beyond simply thinking about the microbiome in dealing with pain to considering the microbiome as central in multimodal pain prevention and management strategies. The microbiome is key in any attempts to change physiology, metabolism, systems biology function, and receptor-based perceptions within the human body.

show abstract

Opioid system influences gut-brain axis: Dysbiosis and related alterations

Cited by 40 publications

References 141 publications

Sex‐dependent impact of microbiota status on cerebral μ‐opioid receptor density in fischer rats

Sex‐dependent impact of microbiota status on cerebral μ‐opioid receptor density in fischer rats

The Role of Dysbiosis in Critically Ill Patients With COVID-19 and Acute Respiratory Distress Syndrome

Microbiome First Approaches in Pain Prevention and Management

Contact Info

Product

Resources

About